Immunic

$9.12 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Immunic

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Stock Analysis

last close $8.32
1-mo return -16.7%
3-mo return -17.6%
avg daily vol. 158.2T
52-week high 28.21
52-week low 6.96
market cap. $218M
forward pe -
annual div. -
roe -53.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 50.7%
baraka

Subscribe now for daily local and international financial news

Subscribe